Serum HBV DNA plus RNA reflecting cccDNA level before and during NAs treatment in HBeAg positive CHB patients

Wang，Yang1,2; Liu，Yanna3; Liao，Hao3,4; Deng，Zhongping5,6; Bian，Dandan1,2; Ren，Yan1,2; Yu，Guangxin3; Jiang，Yingying1,2; Bai，Li1,2; Liu，Shuang1,2; Liu，Mei1,2; Zhou，Li1,2; Chen，Yu1,2; Chen，Xinyue1; Duan，Zhongping1,2; Lu，Fengmin3; Zheng，Sujun1,2

2022

10.7150/ijms.71737

International Journal of Medical Sciences   影响因子和分区

1449-1907

Background & Aims: Correlations between serum viral markers and intrahepatic cccDNA in patients undergoing long-term nucleos(t)ide analogues (NAs) treatment haven’t been fully explored. In this study, we evaluate the correlation between intrahepatic cccDNA and other serum viral markers and intrahepatic HBV DNA in HBeAg positive chronic hepatitis B (CHB) patients during 60-month treatment with NAs. Methods: Fifty-four HBeAg positive CHB patients received long-term NAs treatment were included in this study. Serial serum samples were regularly collected and quantitatively analyzed for HBsAg, HBV DNA, HBV RNA and HBcrAg. Histological samples from liver biopsy at baseline and month 60 were analyzed for intrahepatic HBV DNA and cccDNA. Results: At baseline, serum HBV DNA plus RNA was positively associated with intrahepatic cccDNA in multivariate regression analysis (β=0.205, P<0.001). In the correlation analysis between cccDNA and serum viral markers, HBV DNA plus RNA had the highest correlation coefficient (r=0.698, P<0.001), followed by serum HBV DNA (r=0.641, P<0.001), HBV RNA (r=0.590, P<0.001), and HBcrAg (r=0.564, P<0.001). At month 60, correlations between these serum viral markers and cccDNA were not observed (P>0.05). Multivariate regression analysis showed that only the decreased HBV DNA plus RNA was positively associated with cccDNA decline (β=0.172, P =0.006). Changes of HBV DNA plus RNA (r=0.525, P=0.001) was better correlated with cccDNA decline as compared to HBV RNA (r=0.384, P=0.008), HBV DNA (r=0.431, P=0.003), and HBsAg (r=0.342, P=0.029). Conclusions: Serum HBV DNA plus RNA better correlated with intrahepatic cccDNA than other viral makers before and during NAs treatment in HBeAg positive CHB patients.

chronic hepatitis B covalently closed circular DNA hepatitis B surface antigen nucleos(t)ide analogues pregenomic RNA

SCI

英语

其他

National Science and Technology Key Project on "Major Infectious Diseases such as HIV/AIDS, Viral Hepatitis Prevention and Treatment"["2017ZX103 02201-004","2017ZX10202203-006","2017ZX10201201","201 7ZX10203201-005"] ; Beijing Municipal Administration of Hospitals Clinical medicine Development[ZYLX202125]

General & Internal Medicine

Medicine, General & Internal

WOS:000805434500010

IVYSPRING INT PUBL

2-s2.0-85130962042

Scopus

1.Liver disease center,Beijing YouAn Hospital,Capital Medical University,Beijing,100069,China
2.Beijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment & Research,Beijing YouAn Hospital,Capital Medical University,Beijing,100069,China
3.Department of Microbiology and Infectious Disease Center,School of Basic Medical Sciences,Peking University Health Science Center,Beijing,100191,China
4.Department of Clinical Laboratory,Shenzhen Third People’s Hospital,Southern University of Science and Technology,National Clinical Research Center for Infectious Diseases,Shenzhen,518112,China
5.Academy for Advanced Interdisciplinary Studies,Peking University,Beijing,100871,China
6.Hunan Provincial Key Laboratory of Gene Diagnostic Technology,Changsha,410205,China

Wang，Yang,Liu，Yanna,Liao，Hao,et al. Serum HBV DNA plus RNA reflecting cccDNA level before and during NAs treatment in HBeAg positive CHB patients[J]. International Journal of Medical Sciences,2022,19(5):858-866.

Wang，Yang.,Liu，Yanna.,Liao，Hao.,Deng，Zhongping.,Bian，Dandan.,...&Zheng，Sujun.(2022).Serum HBV DNA plus RNA reflecting cccDNA level before and during NAs treatment in HBeAg positive CHB patients.International Journal of Medical Sciences,19(5),858-866.

Wang，Yang,et al."Serum HBV DNA plus RNA reflecting cccDNA level before and during NAs treatment in HBeAg positive CHB patients".International Journal of Medical Sciences 19.5(2022):858-866.